» Articles » PMID: 11694537

Decay-accelerating Factor (DAF), Complement Receptor 1 (CR1), and Factor H Dissociate the Complement AP C3 Convertase (C3bBb) Via Sites on the Type A Domain of Bb

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2001 Nov 6
PMID 11694537
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

The AP C3 convertase, C3bBb(Mg(2+)), is subject to irreversible dissociation (decay acceleration) by three proteins: DAF, CR1, and factor H. We have begun to map the factor B (fB) sites critical to these interactions. We generated a panel of fB mutations, focusing on the type A domain because it carries divalent cation and C3b-binding elements. C3bBb complexes were assembled with the mutants and subjected to decay acceleration. Two critical fB sites were identified with a structural model. 1) Several mutations centered at adjacent alpha helices 4 and 5 (Gln-335, Tyr-338, Ser-339, Asp-382) caused substantial resistance to DAF and CR1-mediated decay acceleration but not factor H. 2) Several mutations centered at the alpha 1 helix and adjoining loops (especially D254G) caused resistance to decay acceleration mediated by all three regulators and also increased C3b-binding affinity and C3bBb stability. In the simplest interpretation of these results, DAF and CR1 directly interact with C3bBb at alpha 4/5; factor H likely interacts at some other location, possibly on the C3b subunit. Mutations at the C3b.Bb interface interfere with the normal dissociation of C3b from Bb, whether it is spontaneous or promoted by DAF, CR1, or factor H.

Citing Articles

Autoantibodies against complement factor B in rheumatoid arthritis.

Matola A, Fulop A, Rojkovich B, Nagy G, Sarmay G, Jozsi M Front Immunol. 2023; 14:1113015.

PMID: 36891314 PMC: 9986603. DOI: 10.3389/fimmu.2023.1113015.


Substitutions at position 263 within the von Willebrand factor type A domain determine the functionality of complement C2 protein.

Kuzniewska A, Thiel M, Kowalska D, Felberg-Mietka A, Szynkowski P, Oldziej S Front Immunol. 2023; 13:1061696.

PMID: 36591303 PMC: 9797810. DOI: 10.3389/fimmu.2022.1061696.


An Evaluation of the Complement-Regulating Activities of Human Complement Factor H (FH) Variants Associated With Age-Related Macular Degeneration.

Biggs R, Makou E, Lauder S, Herbert A, Barlow P, Katti S Invest Ophthalmol Vis Sci. 2022; 63(12):30.

PMID: 36445700 PMC: 9716232. DOI: 10.1167/iovs.63.12.30.


CipA mediates complement resistance of by formation of a factor I-dependent quadripartite assemblage.

Ries J, Hess M, Nouri N, Wichelhaus T, Gottig S, Falcone F Front Immunol. 2022; 13:942482.

PMID: 35958553 PMC: 9361855. DOI: 10.3389/fimmu.2022.942482.


The emerging role of complement in neuromuscular disorders.

Lee J, Woodruff T Semin Immunopathol. 2021; 43(6):817-828.

PMID: 34705082 DOI: 10.1007/s00281-021-00895-4.